Health and Fitness Health and Fitness
Tue, November 6, 2012
Mon, November 5, 2012
Sat, November 3, 2012
Fri, November 2, 2012
Thu, November 1, 2012
Wed, October 31, 2012
Tue, October 30, 2012
Mon, October 29, 2012
Sun, October 28, 2012
Fri, October 26, 2012
Thu, October 25, 2012
Wed, October 24, 2012
Tue, October 23, 2012
Mon, October 22, 2012
Sun, October 21, 2012
Sat, October 20, 2012
Fri, October 19, 2012
Thu, October 18, 2012
Wed, October 17, 2012
Tue, October 16, 2012
Mon, October 15, 2012
Sun, October 14, 2012
Fri, October 12, 2012
Thu, October 11, 2012
Wed, October 10, 2012
Tue, October 9, 2012

Mylan Files Expedited Motion in Relation to Pioglitazone


Published on 2012-10-23 11:15:43 - Market Wire
  Print publication without navigation


Mylan Files Expedited Motion in Relation to Pioglitazone -- PITTSBURGH, Oct. 23, 2012 /PRNewswire/ --

PITTSBURGH, Oct. 23, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: [ MYL ]) today announced that it has filed an expedited motion in the U.S. District Court for the District of Columbia to stay the Court's order related to Watson's abbreviated new drug application (ANDA) for pioglitazone, pending appeal. The U.S. Food and Drug Administration (FDA) joined Mylan in its motion.     

Mylan CEO Heather Bresch commented, "Mylan is disappointed in yesterday's ruling regarding pioglitazone and we believe the Court erred in its decision by directly contravening the Hatch-Waxman Act. Mylan does not believe Watson is entitled to participate in Mylan's 180-day exclusivity period in relation to this product and we intend to pursue this case vigorously, including seeking expedited relief from the appellate court if necessary."

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. [ mylan.com ]

SOURCE Mylan Inc.




Publication Contributing Sources